美股异动｜默沙东一度跌约8.8% Q2营收略低于预期+公布新重组计划

Core Viewpoint - Merck's (MRK.US) stock experienced a significant decline of approximately 8.8%, reaching a low of $76.67, following disappointing second-quarter earnings results [1] Financial Performance - Merck reported a 2% year-over-year decrease in revenue, totaling $15.81 billion, which was slightly below analyst expectations of $15.9 billion [1] - The adjusted earnings per share were $2.17, surpassing analyst forecasts of $2.02 [1] Product Sales - Sales of the HPV vaccine Gardasil plummeted by 55%, primarily due to stagnant demand in the Chinese market and weakened demand in Japan [1] - Excluding China, Gardasil sales still saw a decline of 3% [1] Supply Chain and Future Plans - The company announced an extension of the suspension of HPV vaccine supplies to China until the end of 2025, a significant delay from the earlier expectation of resuming supplies mid-year [1] - Merck plans to cut annual spending by $3 billion and will reduce positions in administrative, sales, and research departments [1]